Abstract
Topical drugs have been used successfully to treat acne for decades. This review discusses
the use, efficacy, and safety of options available via prescription. Topical antibiotics,
dapsone, benzyl peroxide, azelaic acid, and topical retinoids are included. Topical
antibiotics should not be used as monotherapy but rather be combined with other agents
to avoid resistant Propionibacterium acnes strains. Benzoyl peroxide is effective in preventing bacteria resistance. Topical
retinoids address primarily the comedonal but also the inflammatory lesions of acne.
Azelaic acid is useful in treating acne lesions and for lightening postinflammatory
hyperpigmentation that may accompany inflammatory acne lesions. Combinations of agents
that address different aspects of acne pathogenesis may offer higher benefit to acne
patients.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinics in DermatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- European evidence-based (S3) guideline for the treatment of acne-update 2016-short version.J Eur Acad Dermatol Venereol. 2016; 30: 1261-1268
- Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition.Infect immun. 1982; 35: 71-78
- An overview of topical antibiotics for acne treatment.Dermatology. 1998; 196: 130-134
- Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients.Br J Dermatol. 1990; 122: 233-244
- Treatment of acne with topical antibiotics: lessons from clinical studies.Br J Dermatol. 2005; 153: 395-403
- Topical clindamycin versus oral tetracycline and placebo in acne vulgaris.Scand J Infect Dis Suppl. 1984; 43: 71-75
- Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris.Cutis. 1980; 26 (429): 424-425
- Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris.Br J Dermatol. 1987; 116: 387-391
- A double-blind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris.Acta Derm Venereol. 1990; 70: 534-537
- Antibiotic resistant acne.Cutis. 1976; 17: 593-596
- Systematic review of antibiotic resistance in acne: an increasing topical and oral threat.Lancet Infect Dis. 2016; 16: e23-e33
- Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy.Br J Dermatol. 1992; 126: 586-590
- Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle.Acta Derm Venereol. 2002; 82: 260-265
- Microbial symbiosis with the innate immune defense system of the skin.J Invest Dermatol. 2011; 131: 1974-1980
- Effect of antibiotics on the oropharyngeal flora in patients with acne.Arch Dermatol. 2003; 139: 467-471
- Antibiotic treatment of acne may be associated with upper respiratory tract infections.Arch Dermatol. 2005; 141: 1132-1136
- The combined use of topical benzoyl peroxide and tretinoin in the treatment of acne vulgaris.Int J Dermatol. 1979; 18: 489-496
- Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris.J Drugs Dermatol. 2007; 6: 607-615
- A review of the use of combination therapies for the treatment of acne vulgaris.J Am Acad Dermatol. 2003; 49: S200-S210
- Allergic contact dermatitis caused by topical antiacne drugs.Exp Rev Clin Pharmacol. 2015; 8: 377-381
- The in-vitro antimicrobial effects of azelaic acid upon Propionibacterium acnes strain P37.J Antimicrobial Chemother. 1991; 28: 843-853
- Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne.Acta Derm Venereol Suppl. 1989; 143: 31-34
- Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases.Arch Dermatol Res. 1991; 283: 162-166
- Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts: possible implication of PPARgamma.Exp Dermatol. 2013; 22: 41-47
- Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation.Exp Dermatol. 2010; 19: 813-820
- Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.J Am Acad Dermatol. 2013; 69: 570-577
- Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro.J Invest Dermatol. 1989; 93: 70-74
- Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. An in vivo and in vitro study.Acta Derm Venereol Suppl. 1989; 143: 20-30
- Beneficial effect of 15% azelaic acid cream on acne vulgaris.Br J Dermatol. 1983; 109: 45-48
- The effect of azelaic acid on acne.Br J Dermatol. 1983; 109: 723-724
- Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne.J Eur Acad Dermatol Venereol. 2007; 21: 320-325
- Long-term treatment of acne with 20% azelaic acid cream.Acta Derm Venereol Suppl. 1989; 143: 40-44
- Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin.Acta Derm Venereol Suppl. 1989; 143: 35-39
- The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora.Br J Dermatol. 1995; 132: 204-208
- Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%.Cutis. 2008; 82: 417-421
- Benzoyl peroxide lotion (20 percent) in acne.Cutis. 1980; 25: 90-92
- Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris.Br J Dermatol. 1983; 108: 199-204
- Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations.J Am Acad Dermatol. 1997; 37: 590-595
- Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris.Int J Dermatol. 1978; 17: 246-251
- Single-blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% gel (QD) in the treatment of acne vulgaris for 11 weeks.J Dermatol Treat. 2003; 14: 166-171
- The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial.J Drugs Dermatol. 2013; 12: 1033-1038
- An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients.J Am Acad Dermatol. 2008; 59: 792-800
- A multicentre, randomized, single-blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once-daily gel versus clindamycin 1% twice-daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients.J Eur Acad Dermatol Venereol. 2016; 30: 1176-1182
- A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris.J Drugs Dermatol. 2010; 9: 131-136
- A new, once-daily, optimized, fixed combination of clindamycin phosphate 1.2% and low-concentration benzoyl peroxide 2.5% gel for the treatment of moderate-to-severe acne.J Clin Aesthetic Dermatol. 2009; 2: 44-48
- Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.J Drugs Dermatol. 2011; 10: 1382-1396
- An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris.J Drugs Dermatol. 2014; 13: 1083-1089
- The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable.J Drugs Dermatol. 2015; 14: 381-384
- Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients.J Dermatol Treat. 2011; 22: 197-205
- Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study.J Am Acad Dermatol. 2007; 57: 791-799
- Absence of degradation of tretinoin when benzoyl peroxide is combined with an optimized formulation of tretinoin gel (0.05%).J Clin Aesthetic Dermatol. 2010; 3: 26-28
- Benzoyl peroxide in acne.J Am Acad Dermatol. 1989; 20: 518-520
- Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids.J Drugs Dermatol. 2005; 4: 41-47
- Update in retinoid therapy of acne.Dermatol Ther. 2006; 19: 272-279
- Topical tretinoin in acne therapy.J Am Acad Dermatol. 1998; 39: S38-S44
- Evaluating tretinoin formulations in the treatment of acne.J Drugs Dermatol. 2014; 13: 466-470
- Short contact therapy of acne with tretinoin.J Dermatol Treat. 2013; 24: 374-376
- Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris.Int J Dermatol. 1998; 37: 54-55
- Comparison of the stability of topical isotretinoin and topical tretinoin and their efficacy in acne.J Am Acad Dermatol. 1988; 19: 486-491
- Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial.Br J Dermatol. 2002; 147: 523-527
- A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris.Dermatology. 1999; 199: 242-247
- A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials.Br J Dermatol. 1998; 139: 48-56
- A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne.Cutis. 2009; 84: 110-116
- Adapalene 0.3% for the treatment of acne in women.J Clin Aesthetic Dermatol. 2013; 6: 32-35
- Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV).J Cosmetic Dermatol. 2013; 12: 103-107
- Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.Cutis. 2002; 69: 12-19
- Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study.J Cosmetic Laser Ther. 2004; 6: 79-85
- A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.Cutis. 2002; 69: 4-11
- Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.J Drugs Dermatol. 2010; 9: 549-558
- Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel.Arch Dermatol. 2002; 138: 481-489
- Tazarotene combination leads to efficacious acne results trial study G. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy.Cutis. 2002; 69: 20-29
- Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.J Drugs Dermatol. 2006; 5: 256-261
- Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.J Drugs Dermatol. 2007; 6: 981-987
- Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.J Am Acad Dermatol. 2007; 56 (439 e431-410)
- Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials.J Drugs Dermatol. 2016; 15: 553-561
- Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials.J Drugs Dermatol. 2016; 15: 962-969
- The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.J Drugs Dermatol. 2012; 11: 1417-1421
- Comparative efficacy and tolerability of dapsone 5% gel in adult versus adolescent females with acne vulgaris.J Clin Aesthetic Dermatol. 2015; 8: 31-37
- Use of dapsone 5% gel as maintenance treatment of acne vulgaris following completion of oral doxycycline and dapsone 5% gel combination treatment.J Drugs Dermatol. 2016; 15: 191-195
Article info
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
